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Abstract
Introduction Electronic healthcare data have several
advantages over prospective observational studies, but the
sensitivity of data on neurodevelopmental outcomes and its
comparability with data generated through other method-
ologies is unknown.
Objectives The objectives of this study were to determine
whether data from the UK Clinical Practice Research
Datalink (CPRD) produces similar risk estimates to a
prospective cohort study in relation to the risk of neu-
rodevelopmental disorders (NDDs) following prenatal
antiepileptic drug (AED) exposure.
Methods A cohort of mother–child pairs of women with
epilepsy (WWE) was identified in the CPRD and matched
to a cohort without epilepsy. The study period ran from
1 January 2000 to 31 March 2007 and children were
required to be in the CPRD at age 6 years. AED exposure
during pregnancy was determined from prescription data
and children with an NDD diagnosis by 6 years were
identified from Read clinical codes. The prevalence and
risk of NDDs was calculated for mother–child pairs in
WWE stratified by AED regimen and for those without
epilepsy. Comparisons were made with the results of the
prospective Liverpool and Manchester Neurodevelopment
Group study which completed assessment on 201 WWE
and 214 without epilepsy at age 6 years.
Results In the CPRD, 1018 mother–child pairs to WWE
and 6048 to women without epilepsy were identified. The
CPRD identified a lower prevalence of NDDs than the
prospective study. In both studies, NDDs were more fre-
quently reported in children of WWE than women without
epilepsy, although the CPRD risk estimate was lower (2.16
vs. 0.96%, p\ 0.001 and 7.46 vs. 1.87%, p = 0.0128).
NDD prevalence differed across AED regimens but the
CPRD data did not replicate the significantly higher risk of
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NDDs following in utero monotherapy valproate exposure
(adjusted odds ratio [ORadj] 2.02, 95% confidence interval
[CI] 0.52–7.86) observed in the prospective study (ORadj
6.05, 95% CI 1.65–24.53).
Conclusion It was possible to identify NDDs in the CPRD;
however, the CPRD appears to under-record these out-
comes. Larger studies are required to investigate further.
Key Points
The results of this study suggest that
neurodevelopmental disorders are under-recorded in
the Clinical Practice Research Datalink.
Accurate recording within electronic healthcare
databases should be encouraged given their
increasing use in the evaluation of medication safety.
It is important to generate risk estimates from a
number of sources and understand the strengths and
weaknesses of the methodological types in order to
aid the translation of research findings to the clinic
for pre-conceptual counselling.
1 Introduction
The use of electronic healthcare databases containing
anonymised, routinely collected healthcare data for thera-
peutic adverse event monitoring is increasing. This
approach has the potential to offer several advantages over
prospective observational studies, including larger cohort
size and immediately available, prospectively recorded,
longitudinal population-level data. The sensitivity of such
routinely collected data for the detection of associations
with adverse neurodevelopmental outcomes and its com-
parability with data generated through prospective longi-
tudinal cohort studies is, however, unknown.
Neurobehavioural/neurodevelopmental teratogens are
agents that may adversely impact the neuropsychological
and behavioural functioning of an individual who was
exposed to that agent in utero. However, established ter-
atogen surveillance systems are generally designed to
identify structural teratogenic effects through monitoring
rates of birth defects in exposed offspring at birth. As a
result, for most medicines, data on longer-term develop-
ment are absent and an effect on cognition or behaviour
may go undetected for many years. This is evidenced by
the findings of the recent European-wide review on sodium
valproate, an antiepileptic drug (AED) with a prior well-
established physical embryopathy but which is only now
recognised to carry a significant risk of lifelong develop-
mental effects into adulthood [1]. The possibility of using
electronic healthcare records to detect signals of neurobe-
havioural teratogenicity in ‘real-time’ is therefore a very
attractive proposition, especially for newer AEDs and
medicines such as antidepressants that are frequently pre-
scribed during pregnancy.
Although almost consistently identified, risk estimates
vary regarding the neurodevelopmental effects of valproate
exposure in utero, with prevalence estimates for autism
ranging from 3 to 17% [2–5]. Christensen et al. [5] reported
an increased prevalence of autism following exposure to
valproate using Danish electronic healthcare data, but these
rates were lower than those reported by an earlier UK-based
prospective study by Bromley et al. [2] and in other
prospective cohort studies [3, 4]. This raises questions about
the utility of using electronic healthcare databases for neu-
robehavioural teratogen signal detection, or to quantify risk,
given the subtle and varying patterns with which neurode-
velopmental disorders (NDDs) may present. It is evident that
not all electronic healthcare databases are equivalent, and
while some offer national population data that have been
systematically collected over long periods, others, such as
the Clinical Practice Research Datalink (CPRD), cover lar-
gely primary care data for a proportion of the UK population
only. CPRD data have previously been found to have a
reduced prevalence of structural malformations in children
exposed to valproate in comparison to a prospective obser-
vational study [6], which raises concerns that NDDs may
also be under-recorded. It is therefore important that the
reliability of routinely collected data to detect neurodevel-
opmental outcomes in children is investigated and that both
healthcare providers and patients understand how risk esti-
mates generated from electronic healthcare data compare
with those from face-to-face reviews.
This study therefore aimed to determine whether data
from the UK’s CPRD produced similar risk estimates to a
prospective UK longitudinal face-to-face study, conducted
by the Liverpool and Manchester Neurodevelopment
Group [2], in relation to the risk of specific NDDs fol-
lowing prenatal exposure to AEDs.
2 Methods
2.1 Overview
Data from the CPRD were analysed to assess the preva-
lence of child neurodevelopmental outcomes for individual
AEDs. The CPRD analysis mirrored the Liverpool and
Manchester prospective UK cohort study as closely as
possible to enable comparison of the findings from each
dataset.
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2.2 Clinical Practice Research Datalink (CPRD)
The CPRD contains anonymised, longitudinal patient
medical and prescribing records routinely collected within
general practice. As of July 2013 it contained data on over
11 million patients and was actively collecting data on
*6.9% of the UK population [7]. Data are entered as Read
clinical codes and include information relating to preg-
nancy, symptoms and diagnoses, referrals and issued pre-
scriptions. In addition to Read codes, general practitioners
(GPs) can enter, alongside the coded entry, additional
detail as non-coded ‘free text’. At the time of the study,
anonymised free text could be requested from the database
provider to help verify a Read code diagnosis, and for
patients currently registered in the database it was possible
to request an anonymised photocopy of their full paper
medical record. However, access to the free-text service
ceased in October 2013 due to changes in governance
requirements.
2.3 Liverpool and Manchester Study
The prospective cohort of the Liverpool and Manchester
Neurodevelopment Group [2, 8] consisted of women with
epilepsy (WWE) and women without epilepsy recruited
between 2000 and 2004 from 11 hospital antenatal clinics
in North-West England. For each pregnant woman with
epilepsy a woman without epilepsy was identified by
reviewing records to identify women who had attended the
antenatal clinic on the same date. Women were matched on
age, parity, residential district and employment. When
recruited into the study during their pregnancy, women
were asked about their exposure to AEDs during preg-
nancy. The offspring were then followed prospectively and
at the 6-year assessment parents were asked about the
health and development of their child, including any
diagnoses of physical or developmental difficulties such as
autistic spectrum disorder (ASD), attention–deficit hyper-
activity disorder (ADHD) and/or dyspraxia that had been
made independently of the research team. A positive report
was followed up to confirm the diagnosis with the relevant
medical records (i.e. specialist letters) or the healthcare
professional/school. Outcome data at 6 years were col-
lected for 201 children born to WWE (175 AED exposed,
26 unexposed) and 214 born to women without epilepsy.
Further details of the study can be found elsewhere [2, 8]
and a summary is shown in Fig. 1.
2.4 CPRD study population
All pregnancies to WWE were identified in the CPRD,
where the pregnancy ended in a live delivery between 1
January 2000 and 31 December 2006. Women were
required to have been followed in the CPRD throughout
pregnancy and for the 6 months prior. WWE were identi-
fied based on a combination of epilepsy diagnosis codes,
seizure codes and AED prescriptions (See Electronic
Supplementary Material 1). The start date of each preg-
nancy was estimated using an algorithm that incorporated
information from all pregnancy-related codes in the
woman’s record [9]; where insufficient information was
available (18.8% of pregnancies) a default duration of
280 days was assigned. The medical records of the mothers
were linked to those of the child using an algorithm
described previously [10]. Linked mother–child pairs were
included if the child was still registered in the CPRD at age
6 years and 3 months; this cut-off was chosen as most
children in the prospective study were assessed shortly
after their sixth birthday. Each eligible WWE mother–child
pair was randomly matched to six mother–child pairs
where the mother did not meet the epilepsy criteria and had
not been prescribed an AED at any time prior to her child
turning age 6 years. Mother–child pairs were matched on
maternal age, year of delivery, sex of the child and GP
practice as a proxy for socioeconomic status (or the
socioeconomic status of the GP practice where GP practice
matching was not possible).
All AED prescriptions issued to WWE during preg-
nancy or the 6 months prior were identified. The duration
of each prescription was calculated based on an algorithm
that used information on the number of tablets dispensed
and the dosage instruction. The prescriptions were then
mapped, taking into account evidence of polytherapy use or
drug switching. Based on the mapped prescriptions, AED
exposure during the 6 months before pregnancy and
between the start and end of pregnancy was determined. As
with the Liverpool and Manchester study, treatment was
classed as polytherapy where the woman was prescribed a
second AED (including a benzodiazepine) for any length of
time.
In line with the Liverpool and Manchester study, the
NDD outcomes of interest were ASD, ADHD and dys-
praxia. All children in the study population with a diag-
nosis recorded by age 6 years and 3 months were identified
based on Read codes in their electronic record. The study
period was chosen to ensure all children reached the age
cut-off by 30 April 2013, when the fifth edition of the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) was introduced; this avoided any potential dif-
ferences due to the changes in terminology and definitions
of the outcomes of interest between the fourth (DSM-IV)
and fifth editions. The NDDs identified were verified by
requesting full photocopied medical records for infants still
registered in the CPRD and ‘free text’ for those no longer
registered or where there was no response to the photo-
copied record request. These were reviewed by authors RC,
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RB, AW and LY, who were blinded to the maternal
medication exposure status of the child.
Covariate information was extracted on maternal
smoking status, alcohol consumption, quintile of depriva-
tion at a GP practice level, folic acid 5 mg and seizures
during pregnancy. As with the Liverpool and Manchester
study, mother–child pairs were excluded if one or both had
evidence of a diagnosis likely to influence neurodevelop-
mental outcome (e.g. neurofibromatosis, Down’s
syndrome).
2.5 Analysis
The prevalence of NDDs was determined for mother–child
pairs with epilepsy stratified by AED treatment regimen
during pregnancy and for those in the matched group
without epilepsy. Conditional logistic regression was used
to determine the likelihood of an NDD diagnosed by age
6 years and 3 months in the children of WWE exposed to
different AED regimens during pregnancy compared with
women who did not have epilepsy. Adjustments were made
for any covariates where p\ 0.2 in the univariate analysis.
To compare the results of this CPRD study and the face-to-
face study, differences between the proportions of NDDs
identified in the two studies for each treatment regimen
were calculated along with 95% confidence intervals [CIs]
of these differences [11]. Primary analyses included all
NDD outcomes that could be verified as well as those
where there was insufficient information to verify or refute
the diagnosis. A sensitivity analysis was carried out
restricted to NDDs where the diagnosis could be verified.
An additional sensitivity analysis was later carried out
extending the AED exposure window to include the
6 months before the start of pregnancy in addition to the
pregnancy itself. This was because the dosage instructions
recorded in the CPRD for women who discontinued ther-
apy did not appear to allow for a gradual reduction in dose
and it is likely that women will titrate down and not dis-
continue AED therapy abruptly. It is therefore possible that
some women categorised by the prescription mapping as
being AED unexposed during pregnancy actually contin-
ued the medication they were taking prior to pregnancy for
considerably longer than the dosage instructions suggested,
resulting in them having been exposed during the early
weeks of gestation.
3 Results
Within the CPRD, 1030 eligible mother–child pairs were
identified where the mother had epilepsy and these were
matched to 6180 mother–child pairs without epilepsy.
Seventy-one infants and one mother (1.0%) had a Read
code for a condition that could influence neurodevelop-
mental outcome (see Electronic Supplementary Material 2)
and these 72 mother–child pairs were excluded from the
study. Of those excluded, 12 were in the epilepsy cohort
and therefore their respective six matched mother–child
pairs were also excluded. After exclusions, the final study
cohort included 7066 mother–child pairs: 1018 WWE and
6048 women without epilepsy. Fifty-four percent of WWE
received an AED during pregnancy: 79% monotherapy and
Liverpool and Manchester Neurodevelopment Group study CPRD study
Study populaon Study populaon
Pregnant women with a reported history of epilepsy Pregnant women with epilepsy based on coded data in their
recruited from antenatal clinics electronic medical record
Exposure data Exposure data
AED exposure during pregnancy determined by maternal AED exposure during pregnancy determined from issued
interview and medical notes prescripon records
Comparator populaon Comparator populaon
Pregnant women without epilepsy recruited from antenatal Pregnant women without epilepsy based on coded data in
clinics at a 1:1 rao matched on age, parity, residenal district their electronic medical record at a 1:6 rao matched on age,
(postcode) and employment sex of the oﬀspring, year of delivery and GP pracce (proxy for
residenal district and socioeconomic status)
Outcome data Outcome data
Informaon collected at the 6-year follow-up assessment NDD outcome data for infants sll registered in the CPRD at
NDD diagnosis made through roune clinical services idenﬁed by the age of 6 years and 3 months based on coded data in their
maternal interview and veriﬁed by medical notes or electronic medical record and veriﬁed by supporng evidence
follow-up with the relevant healthcare professional in the form of free text or photocopied records
Fig. 1 Summary of selection of the study cohorts. AED antiepileptic drug, CPRD Clinical Practice Research Datalink, GP general practitioner,
NDD neurodevelopmental disorder
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21% polytherapy. WWE were more likely than women
without epilepsy to be smokers (p\ 0.001) but were less
likely to drink alcohol (p\ 0.001); this mirrored the
Liverpool and Manchester cohort [2]. Characteristics of the
two study cohorts are shown in Table 1.
Eighty-seven Read code diagnoses, in 84 children, were
identified for one of the NDDs of interest: 47 for ASD, 30
for ADHD, four for dyspraxia and three children had codes
for both ASD and ADHD. Verification of the outcomes
resulted in 63 being verified, four being refuted and for 20
there was insufficient information to confirm or refute (see
Electronic Supplementary Material 3). Four of the mother–
child pairs excluded from the study cohort, due to evidence
of a condition that could influence neurodevelopment, had
one of the outcomes of interest: two in the epilepsy cohort
(one valproate polytherapy exposed and one unexposed to
AEDs) and two in the non-epilepsy cohort. In addition, one
child was identified as having ADHD based on a Read code
and review of the free text confirmed this diagnosis and
also provided evidence of an ASD diagnosis, even though
no ASD Read codes were present.
In both the CPRD and the Liverpool and Manchester
study, NDDs were more frequently reported in the children
of WWE than children of women without epilepsy,
although the risk estimate was much lower in the CPRD
(2.16 vs. 0.96%, p\ 0.001 and 7.46 vs. 1.87%,
p = 0.0128, respectively). The prevalence of NDDs varied
by specific AED exposure in both study cohorts (Tables 2,
3). In the CPRD, the prevalence of NDDs was increased
amongst offspring antenatally exposed to carbamazepine,
valproate (monotherapy and polytherapy) and non-val-
proate polytherapy combinations when compared with
offspring born to women without epilepsy, but these
increases did not reach statistical significance (Table 2).
In the CPRD cohort, a significant increase in NDD risk
was observed in the offspring of WWE and no AED
exposure when compared with women without epilepsy.
However, the two sensitivity analyses restricting NDDs to
those that could be verified and extending the AED expo-
sure window no longer demonstrated a significant increase
in NDD risk (see Electronic Supplementary Material 4 and
Table 4). When extending the AED exposure window to
include the period 6 months before pregnancy, manual
review of the electronic prescription records for the nine
NDD cases in this group revealed that the algorithm pre-
dicted that two women had discontinued valproate just
prior to pregnancy (one case of valproate monotherapy and
the other of valproate polytherapy). The calculated pre-
scription durations had estimated discontinuation at
B10 weeks prior to conception; however, such predictions
were based on estimated routine daily dose information and
did not take into account the likely slow tapering of the
medications prior to discontinuation. If tapering did occur
this could have extended the time window of exposure so
that it overlapped with early gestation. Extending the AED
exposure window resulted in a significant increase in risk
for valproate polytherapy (adjusted odds ratio [ORadj] 7.32
[95% CI 1.65–32.57]) and increased the risk estimate for
valproate monotherapy (ORadj 2.97 [95% CI 0.84–10.49]),
although this still did not reach statistical significance.
The prevalence of NDDs in the CPRD, with the
exception of the carbamazepine and epilepsy and no AED
exposure cohorts, was lower than in the Liverpool and
Manchester study (Fig. 2). Analysis to look at the differ-
ences in proportions found that for ‘lamotrigine’, ‘val-
proate’ and the ‘other monotherapy’ categories, the
proportion of NDDs observed in the CPRD was signifi-
cantly lower than in the Liverpool and Manchester study,
although the CIs were wide (Table 5). The proportions of
NDDs observed for all WWE and WWE who had AED
exposure were also significantly lower in the CPRD than in
the face-to-face study. The exposure window sensitivity
analysis did not alter these findings, although the
‘monotherapy other’ category did reduce to borderline
significance. In contrast to the Liverpool and Manchester
study, the CPRD data did not reproduce the significant
increased risk of NDDs at 6 years and 3 months following
in utero exposure to valproate [2].
4 Discussion
This study identified a lower prevalence of NDDs in the
CPRD data than in the Liverpool and Manchester cohort,
both overall and for certain AED exposure groups. Using
data from the CPRD it was possible to reproduce the sig-
nificant increase in risk of NDDs in WWE compared with
women without epilepsy, but it was not possible to repro-
duce the significant association for valproate monotherapy
exposure, although the point estimate did fall within the
corresponding CI of the Liverpool and Manchester study.
Analysis of the CPRD data did identify an increased risk of
NDDs in WWE who had no AED exposure during preg-
nancy, but this was no longer significant following sensi-
tivity analyses. The sensitivity analysis to extend the time
window of exposure to include the 6 months before preg-
nancy, allowing for a longer duration of exposure resulting
from the likely tapering of AED dose before discontinua-
tion, resulted in a significant increase in risk following
valproate polytherapy exposure and a small increase for
valproate monotherapy, although this still did not reach
statistical significance.
The lower prevalence of NDDs in the CPRD, in com-
parison with the Liverpool and Manchester study, suggests
potential under-recording of NDDs within the CPRD and
this is evidenced in a number of ways. The overall
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prevalence of all three NDDs combined in the CPRD
cohort for women without epilepsy was 0.96% and this is
lower than the background population prevalence of ASD
alone, which is estimated to be between 1.16 and 1.57% in
the UK general population [12, 13]. The rate of NDDs
within the CPRD study cohort was also lower than other
prospective observational cohort studies where rates fol-
lowing valproate monotherapy exposure ranged from 3.8 to
8.9% [2–4]. Finally, the rate of NDDs in the CPRD was
also lower than those reported by the only other electronic
healthcare record study assessing specific
neurodevelopmental outcomes for AEDs [5]. In this
nationwide population-based study, Christensen and col-
leagues [5], using routinely collected Danish healthcare
and pharmacy records, identified a prevalence for all ASDs
within a cohort of monotherapy valproate exposed infants
of 3.09% (12/3881). Although this prevalence is still low in
comparison with the Liverpool and Manchester and other
Table 1 Characteristics of the two study populations
Characteristic CPRD Liverpool and Manchester Neurodevelopment
Groupa
Women with epilepsy
[n (%)]
Comparator (no epilepsy)
[n (%)]
Women with epilepsy
[n (%)]
Comparator (no epilepsy)
[n (%)]
Mother–child pairs (n) 1018 6048 201 214
Mean maternal age at pregnancy
(years)
28.9 28.9 28 29
Sex of the child (% male) 50.2 50.2 57.1 51.9
Smoking status
Non-smoker 506 (49.7) 3308 (54.7) 144 (71.6) 180 (84.1)
Smoker 360 (35.4) 1759 (29.1) 55 (27.4) 34 (15.9)
Ex-smoker 151 (14.8) 968 (16.0)
Unknown 1 (0.1) 13 (0.2) 2 (1.0) 0 (0.0)
Alcohol drinking status
Teetotal 190 (18.7) 853 (14.1) 165 (82.1) 148 (69.2)
Drinks alcohol 684 (67.2) 4388 (72.6) 36 (17.9) 66 (30.8)
Heavy drinker 8 (0.8) 42 (0.7)
Ex-drinker 50 (4.9) 181 (3.0)
Unknown 86 (8.4) 584 (9.7) 2 (1.0) 0 (0.0)
SES quintile
1 (least deprived) 155 (15.2) 921 (15.2)
2 169 (16.6) 1005 (16.6)
3 202 (19.8) 1195 (19.8)
4 226 (22.2) 1345 (22.2)
5 (most deprived) 266 (26.1) 1582 (26.2)
Professional 62 (30.8) 87 (40.7)
Folic acid
5 mg in 6 months
pre-pregnancyb
196 (35.9)
Preconception use 97 (48.3) 85 (39.7)
Seizures during pregnancy
Any record 46 (4.5)
Convulsive 68 (33.8)
Non-conclusive 28 (13.9)
CPRD Clinical Practice Research Datalink, SES socioeconomic status
a Figures provided via personal communication
b Folic acid figures restricted to only those prescribed an antiepileptic drug and to 5 mg as this strength is only available on prescription
1 This figure was not reported in the Christensen et al. [5] paper and
is calculated here taking data from the online supplement table e4 of
the Christensen paper.
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observational studies [2, 3], this study, using Danish elec-
tronic healthcare records, did replicate the finding of a
greater risk for the valproate-exposed cohort. The finding
of a lower prevalence in the CPRD is also consistent with
that observed in an earlier CPRD study in which the
prevalence of major congenital malformations within val-
proate-exposed children was lower than that reported by
the UK Epilepsy and Pregnancy Register [6].
The reason for under-recording of NDDs within the
CPRD remains unclear and to our knowledge no study has
reported on the sensitivity of their recording in the CPRD.
It is possible that in some cases only symptoms of a con-
dition are entered as Read codes and the actual diagnosis is
either not entered at all or is only entered as free text or as a
scanned letter from a specialist. This possibility is sup-
ported by the case identified in this study where the free
text reported an ASD diagnosis but no ASD Read code had
been entered. A recent study, using data from The Health
Improvement Network database in the UK, evaluated the
risk of NDDs following exposure to valproate using a
broad range of Read codes describing general develop-
mental delay and behavioural problems, including codes
for speech delay and language difficulties, rather than
specific NDD diagnoses [14]. This study found an almost
three-fold increased risk of a child having a record of one
of these codes in women prescribed valproate during
Table 2 Prevalence of neurodevelopmental disorders and crude and adjusted odds ratios by antiepileptic drug group: Clinical Practice Research
Datalink study
AED exposure during
pregnancy
Total
(n)
No. with
NDD
Prevalence of NDD [% (95%
CI)]
Unadjusted odds
ratioa
Adjusted odds ratiob
(95% CI)
p value
Controls 6048 58 0.96 (0.74–1.25) Reference Reference
WWE no AED 472 9 1.91 (0.93–3.72) 2.01 2.77 (1.21–6.34) 0.01
Carbamazepine 148 5 3.38 (1.25–8.12) 3.61 2.75 (0.92–8.24) 0.07
Lamotrigine 122 0 0.00 (0.00–3.80)
Valproate 118 \5 2.54 (0.66–7.81) 2.69 2.02 (0.52–7.86) 0.5
Other monotherapy 43 0 0.00 (0.00–10.21)
Valproate polytherapy 38 \5 7.89 (2.06–22.48) 8.85
Other polytherapy 77 \5 2.60 (0.45–9.93) 2.75 1.62 (0.32–8.28) 0.6
Null cells result from either no observations or instability of the model due to small numbers
AED antiepileptic drug, CI confidence interval, GP general practitioner, NDD neurodevelopmental disorder, SES socioeconomic status, WWE
women with epilepsy
a Does not account for matching to allow the most direct comparison with the results from the Liverpool and Manchester Neurodevelopment
Group study
b Conditional regression analyses to account for matching on maternal age at pregnancy start, year of delivery, sex of the child and GP practice/
SES of GP practice and adjusts for alcohol drinking status
Table 3 Prevalence of neurodevelopmental disorders and crude and adjusted odds ratios by antiepileptic drug group: study by the Liverpool and
Manchester Neurodevelopment Group (adapted from Bromley et al. [2], with permission)
AED exposure during
pregnancy
Total
(n)
No. with
NDD
Prevalence of NDD [% (95%
CI)]
Unadjusted odds
ratio
Adjusted odds ratioa
(95% CI)
p value
Controls 214 4 1.87 (0.60–5.03) Reference Reference
WWE no AED 26 0 0.00 (0.00–16.02)
Carbamazepine 50 1 2.00 (0.10–12.01) 1.07 1.09 (0.06–7.39) 0.9
Lamotrigine 30 2 6.67 (0.00–23.51) 3.75 4.06 (0.55–22.20) 0.1
Valproate 50 6 12.00 (4.97–25.00) 7.16 6.05 (1.65–24.53) 0.007
Other monotherapy 14 2 14.29 (0.00–43.85) 8.75 8.17 (1.09–49.40) 0.02
Valproate polytherapy 20 3 15.00 (3.96–38.86) 9.26 9.97 (1.82–49.40) 0.005
Other polytherapy 11 1 9.09 (0.48–42.88) 5.25 4.95 (0.25–40.45) 0.2
Null cells result from either no observations or instability of the model due to small numbers
AED antiepileptic drug, CI confidence interval, NDD neurodevelopmental disorder, WWE women with epilepsy
a Variables used in exploratory analysis for consideration in the final model included seizures during pregnancy, maternal IQ, maternal age,
socioeconomic status, alcohol or nicotine exposure, sex and gestational age at birth; a significant association was only found for sex [2]
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pregnancy compared with women not prescribed an anti-
convulsant mood stabiliser. It is possible that these results
may support the theory that GPs are more likely to record
symptom-related codes than specific autism, ADHD and
dyspraxia codes. However, this study did not verify the
Read codes identified, evaluate the sensitivity or speci-
ficity of recording or report on the proportion of children
with specific NDD diagnosis codes. Under-recording could
also potentially occur if there is a delay between a diag-
nosis being made by a specialist and information being
entered into the electronic system and this could have
resulted in misclassification of outcome status for children
in the CPRD diagnosed close to the upper age cut-off.
The percentage of CPRD Read code diagnoses that
could be verified by free text or photocopied records in our
study was higher for ASD than for ADHD and dyspraxia.
This may in part be explained by the age cut-off, with a
recent study demonstrating that approximately 75% of
incident ADHD cases in the CPRD are diagnosed beyond
6 years of age [15]. Within the free text we did find ref-
erences to the fact a child was too young for a formal
diagnosis, so it is possible that GPs are entering an ADHD
code as a working diagnosis but the child is not referred to
receive a definitive diagnosis until they are older. This
should not, however, have affected the comparison with the
Liverpool and Manchester study as the cut-off for age was
matched.
Differences between the CPRD and Liverpool and
Manchester study populations may also explain some of
the observed differences. Both studies matched on maternal
age and a measure of geographical location and socioeco-
nomic status. In the CPRD it was not possible to obtain
reliable information on parity, but to our knowledge this
has not been found to be associated with NDD risk. The
CPRD study matched on the sex of the offspring, which
was not possible in the Liverpool and Manchester study as
recruitment was prenatal. ASD is more common in males
and it is possible that matching may have reduced the level
of association; however, as the Liverpool and Manchester
study adjusted for the sex of the offspring in the statistical
analysis it is unlikely that this will explain the differences
observed. The sample size in the CPRD study was larger,
both in terms of the number of WWE and the use of 1:6
matching, which increased the statistical power and pro-
duced more stable effect estimates with narrower CIs.
However, comparing this study to the larger population
study by Christensen and colleagues [5] demonstrates that
this discrepancy is not purely one of sample size. Obser-
vational studies have in the past ascertained relatively
Table 4 Results of the sensitivity analysis in the Clinical Practice Research Datalink study extending the window of exposure to include
exposure during the 6 months before pregnancy
AED exposure during
pregnancy
Total
(n)
No. with
NDD
Prevalence of NDD
[% (95% CI)]
Unadjusted odds
ratioa
Adjusted odds ratiob
(95% CI)
p value
Controls 6048 58 0.96 (0.74–1.25) Reference Reference
WWE no AED 441 7 1.59 (0.70–3.39) 1.59 2.43 (0.99–6.00) 0.054
Carbamazepine 151 \5 2.65 (0.85–7.07) 2.65 2.38 (0.71–7.96) 0.158
Lamotrigine 121 0 0.00 (0.00–3.84)
Valproate 123 \5 3.25 (1.05–8.62) 3.25 2.97 (0.84–10.49) 0.090
Other monotherapy 40 0 0.00 (0.00–10.91)
Valproate polytherapy 54 5 9.26 (3.46–21.06) 9.26 7.32 (1.65–32.57) 0.009
Other polytherapy 88 \5 2.27 (0.39–8.74) 2.27 1.60 (0.33–7.76) 0.559
AED antiepileptic drug, CI confidence interval, GP general practitioner, NDD neurodevelopmental disorder, SES socioeconomic status, WWE
women with epilepsy
a Does not account for matching to allow the most direct comparison with the results from the Liverpool and Manchester Neurodevelopment
Group study
b Conditional regression analyses to account for matching on maternal age at pregnancy start, year of delivery, sex of the child and GP practice/
SES of GP practice and adjusts for alcohol drinking status
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small cohorts from specialist clinics and may therefore
have included mother–child participants at higher risk of
adverse outcome on the basis of both disease severity and
higher exposure dose. The dose-related effects of valproate
on the fetus have been documented in relation to major
congenital malformations [16], reduced IQ [17] and in the
parental ratings of autistic behaviours [4]. It is thus possible
that ascertainment bias may account for some of the dif-
ferences and that the prevalence rates from observational
studies are higher than those generated by population-
based electronic health record studies as a consequence of
different methodological approaches to data collection.
Differences were also present in the method of recruit-
ment; in the Liverpool and Manchester study women were
enrolled if they reported a history of epilepsy [8], whilst in
the CPRD study identification of epilepsy was dependent
on a combination of Read codes and therapy records.
Approximately 45% of the women identified as having
epilepsy in the CPRD did not receive an AED prescription
during pregnancy. It is possible that some women may
have received their AED prescriptions from secondary
care, resulting in exposure misclassification, although these
numbers are likely to be small as often a specialist will
initiate treatment and repeat prescribing will be continued
by the patient’s GP. However, despite excluding women
with only a single epilepsy code, there may have been
some women with evidence suggestive of epilepsy who did
not have a true diagnosis of epilepsy. A previous study in
the UK has found that approximately 20% of individuals
with a Read code for epilepsy were not listed in their
general practice’s Epilepsy Register and of these only 14%
were on epilepsy medication or had experienced seizures in
the previous year. Unfortunately, it was not possible to
compare the breakdown of AED exposures in the CPRD, as
the Liverpool and Manchester study set out to recruit 50
women to each exposure category rather than WWE in
general [8].
The classification of AED exposure differed between the
two studies, with the Liverpool and Manchester study using
data from maternal interviews and medical notes and the
CPRD using data on the issue of a prescription; as with all
data from electronic records, no information was available
in the CPRD on adherence and whether the medicine was
actually taken as instructed. The finding of an association
between children born to untreated WWE and an increased
risk of NDD was not significant following record verifi-
cation, which was undertaken in a blinded fashion. How-
ever, the possibility of confounding by indication should
always be considered when a positive association between
a maternal exposure and adverse outcome in the child is
observed. It is also possible that exposure misclassification
may have played a role in the differences. In the CPRD, the
prescription records did not appear to allow for a tapering
of dose and in epilepsy AEDs are not routinely discontin-
ued abruptly and tapering can take a number of months
[18]. Manual review of the electronic prescription records
for the nine NDD cases of WWE and reportedly no AED
exposure demonstrated that two women had been estimated
to have discontinued valproate just prior to pregnancy;
however, if tapering of the dose did occur rather than an
abrupt stop (as predicted by the algorithm), their window of
exposure could have been extended to overlap with early
gestation. Such a phenomenon could also be a possible
hypothesis for the findings of others where women who
were predicted to have ‘stopped’ valproate in the 6 months
prior to pregnancy demonstrated an increased risk of hav-
ing a child with an ASD [5]. An association between NDDs
and WWE and no AED exposure has not been reported
before and, therefore, given the lack of its significance
following sensitivity analyses, its reliability is question-
able. These results do highlight the need for sensitivity
analyses when using electronic healthcare data in terms of
the time window of exposure; this would also help account
for any misclassification in the timing of conception and
subsequent exposure at conception.
This study had the strength of being able to make a
direct comparison between the results of two differently
collected datasets of individuals using the same healthcare
system during the same time period and in the same
country. Despite the large size of the CPRD, some aspects
of this study were limited by small numbers of exposed
offspring and this meant it was not possible to determine
whether the CPRD produces accurate measures of relative
Table 5 Comparison of proportions of neurodevelopmental disorders
between the Clinical Practice Research Datalink study and the
Liverpool and Manchester study stratified by antiepileptic drug
exposure
AED exposure
during pregnancy
Difference
between observed
NDD proportions (%)
95% CI
Controls –0.91 –3.76 to 0.27
Women with epilepsy
and no AED
1.91 –11.00 to 3.58
Carbamazepine 1.38 –7.32 to 6.00
Lamotrigine –6.67 –21.55 to –0.77
Valproate –9.46 –21.78 to –0.39
Other monotherapy –14.29 –40.88 to –0.39
Valproate polytherapy –7.11 –29.2 to 9.36
Other polytherapy –6.49 –35.51 to 3.57
All women with
epilepsy
–5.30 –9.94 to –2.12
Women with epilepsy
and an AED
–6.19 –11.50 to –2.38
AED antiepileptic drug, CI confidence interval, NDD neurodevelop-
mental disorder
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risk even though the prevalence estimates are lower.
Restricting the CPRD study population to children still
registered in the CPRD at age 6 years and 3 months had
the benefit of making it directly comparable to the Liver-
pool and Manchester study but did have an impact on
sample size. One of the strengths of electronic healthcare
databases is the longitudinal nature of the data and some
individuals in the cohort will have been followed beyond
6 years of age, but any diagnoses made after this cut-off
were not captured in our study.
5 Conclusion
This study identified a lower prevalence of NDDs in the
CPRD than in a prospective observational study matched
for calendar time and age of the child and did not produce a
signal that valproate as monotherapy is a neurodevelop-
mental teratogen. Consideration of the factors that may
account for this strongly suggest that NDD diagnoses are
under-recorded in this dataset. Data availability, reliability
and completeness varies between electronic healthcare
databases and this may affect the generalisability of our
findings to other data sources. However, the finding of a
potential misclassification of exposure status by estimated
exposure timeframes applies to a large number of elec-
tronic resources and researchers need to give this consid-
eration. As the use of electronic healthcare databases for
the purposes of research increases, accurate recording
should be encouraged as under-recording could have sig-
nificant implications for educating about the risks associ-
ated with in utero exposure. This study has also
demonstrated the value and importance of access to
anonymised information held within the free-text fields of
the CPRD. This has been a key strength of the database and
the fact that this is no longer available will reduce the
validity and quality of the data.
This study highlights the need for feasibility studies and
sensitivity analyses to be carried out before risk assessment
studies are initiated using electronic healthcare databases,
in order to ensure the results can be correctly interpreted.
The difference in findings between the two methodologies
demonstrates the importance of generating risk estimates
from a number of sources, including direct assessment
studies, and that understanding the strengths and weak-
nesses of the methodological types is essential in aiding the
translation of this information to the clinic for pre-con-
ceptual counselling.
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